| HOME >> BIOLOGY >> TECHNOLOGY |
SAN DIEGO, Aug. 5 /PRNewswire/ -- Ceregene, Inc. today announced that the Michael J. Fox Foundation will provide partial funds for long-term follow-up testing of patients enrolled in the company's Phase 2 trial of CERE-120 for Parkinson's disease. The funding will enable Ceregene to collect and analyze more extensive data for up to 48 months from patients with advanced Parkinson's disease who were enrolled in the double-blind, controlled trial which ended in November 2008.
As was previously announced, the Phase 2 trial of CERE-120 involving 52 patients, failed to demonstrate a difference in the primary endpoint between patients in the CERE-120 versus control group. It was subsequently announced, however, that CERE-120 suggested improvement on several secondary endpoints at 12 months, and at 18 months, a statistically significant treatment effect on the primary endpoint emerged, while several additional secondary endpoints also showed improvement. In contrast, on no measure did sham patients perform better than CERE-120 patients, at either 12 or 18 months. Based on those findings, and insight gained from analyses of post-mortem brain tissue from two CERE-120 treated patients, the company has revised the dosing regimen and expects to initiate a new trial of CERE-120 in the near future.
"We are pleased to be able to gather unique, long-term data from both CERE-120 treated and control patients and thus gain more information about the potential long-term effects of CERE-120 on Parkinson's disease," stated Raymond T. Bartus, Ph.D., Ceregene's executive vice president and chief scientific officer. "We very much appreciate the support the MJFF has provided to enable us to expand the testing of these patients and further enrich our data base. Our conviction about CERE-120's potential to treat Parkinson's disease remains strong. We learned a significant amount from the initial Phase 2 trial wh
'/>"/>
| SOURCE Ceregene, Inc. Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinsons Disease
2. Ceregene Announces Two Key Additions to Leadership Team
3. Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
6. Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
7. Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia
8. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
9. SyntheMed Receives US Patent on Novel Polymer Technology
10. Sunesis Receives Approval for Listing on The NASDAQ Capital Market
11. Anesiva Receives NASDAQ Delisting Staff Determination Letter
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |